Tara Berman, MD, MS, is a medical oncologist at Dana-Farber Cancer Institute and a member of faculty at Harvard Medical School in Boston, Massachusetts.
The final takeaways emphasize that antibody drug conjugates are becoming an increasingly important part of gynecologic cancer care, but their successful use depends on staying current with rapidly evolving data and recognizing that these agents are not interchangeable.
Choosing among several possible targets is becoming one of the most practical challenges in modern gynecologic oncology.
Across gynecologic cancers, the future of antibody drug conjugates appears likely to involve more targets, more refined drug design, and a larger role for rational combinations.
Clinical management in recurrent cervical cancer increasingly depends on both practical toxicity prevention and thoughtful biomarker assessment.
Tisotumab vedotin is discussed as an important therapeutic step forward for recurrent or metastatic cervical cancer because it offers clinically meaningful activity in a setting where later line treatment has often been disappointing.
In cervical cancer, antibody drug conjugates are presented as an important advance in a disease where treatment options after progression have historically been limited.
Although antibody drug conjugates have generated real optimism in ovarian cancer, the faculty stress that several key questions remain unresolved before their long term value can be fully defined.
Sequencing multiple antibody drug conjugates is becoming a central question in ovarian cancer as more patients present with overlapping biomarkers and several possible treatment options.
Development of new antibody drug conjugates in ovarian cancer continues to expand beyond folate receptor alpha, and the faculty review why both target selection and trial design will be critical to future success.
A major unmet need in ovarian cancer lies in extending disease control after initial treatment, especially for patients with homologous recombination proficient tumors who often derive less benefit from existing maintenance strategies.
In ovarian cancer, treatment selection for platinum resistant disease is increasingly shaped by biomarkers, prior toxicity, and access to targeted therapy.
Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.
Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.
Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and other emerging targets are generating enthusiasm, particularly because they may broaden treatment options for patients who do not meet narrower biomarker criteria associated with some currently available therapies
Management after progression on immunotherapy remains one of the most difficult areas in endometrial cancer care.
Biomarker testing is presented as a central part of treatment planning in advanced and recurrent endometrial cancer. The faculty review why mismatch repair assessment remains foundational while broader molecular profiling, HER2 immunohistochemistry, and next generation sequencing are increasingly important when selecting later line therapy. Particular attention is given to HER2 expression and to the importance of recognizing potential candidates for trastuzumab deruxtecan before progression narrows treatment opportunities. The discussion underscores a major operational challenge in practice, which is that HER2 testing may still depend on an additional request rather than being built into standard workflows. That gap can delay appropriate treatment selection even as new data continue to expand the relevance of biomarker guided care. The broader point is that pathology processes and testing habits must evolve alongside the therapeutic landscape. A more proactive and comprehensive approach to biomarker assessment is becoming essential for individualized management of recurrent endometrial cancer.
Expert faculty examine how antibody drug conjugates are changing the treatment landscape in endometrial cancer as more patients receive chemotherapy and immunotherapy earlier in care. The discussion centers on the growing need for effective therapies after progression and on why targets such as HER2, folate receptor alpha, TROPE2, B7H4, and CDH6 are drawing interest in recurrent disease. Attention is given to the practical questions clinicians face as these agents move closer to routine use, including how to interpret early phase data, how to think about payload differences, and how to integrate newer options with established treatment approaches. The conversation also highlights the importance of matching enthusiasm with realism, because promising response data must still translate into durable benefit and manageable toxicity. Overall, the faculty outline a rapidly evolving therapeutic space in which antibody drug conjugates may expand options for patients with difficult to treat disease while also introducing more complexity into everyday clinical decision making.
Panelists discuss how emerging antibody-drug conjugates targeting B7-H4 and folate receptors are showing unprecedented 40% to 50% response rates in recurrent endometrial cancer, representing a paradigm shift from historical treatment limitations while highlighting the exciting but challenging landscape of sequencing multiple novel therapies.
Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.
Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss ongoing research to watch in ovarian cancer.
Panelists discuss how the RUBY trial’s real-world data confirms the efficacy of dostarlimab maintenance therapy and surprisingly shows improved quality of life outcomes with delayed time to deterioration compared to placebo, providing confidence in using immunotherapy maintenance despite potential adverse effects.
Panelists discuss how selinexor shows remarkable efficacy in patients with mismatch repair–proficient endometrial cancer, with 40-month progression-free survival compared to 5 months with standard care, while emphasizing the importance of ongoing clinical trials to validate biomarker-driven treatment decisions.
Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for neoadjuvant IMNN-001 plus chemotherapy in advanced epithelial ovarian cancer.
Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Panelists discuss how endometrial cancer treatment has been revolutionized through molecular subtyping into 4 distinct groups (POLE hypermutated, microsatellite instability-high, p53 mutated, and no specific molecular pathology), enabling personalized treatment approaches based on tumor biology rather than just staging.
Panelists discuss how the field is expanding with newer antibody-drug conjugates targeting TROP2, combination immunotherapy approaches, and the critical importance of HPV vaccination as prevention, while addressing social barriers to complex treatment regimens.
Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for radical up-front surgery in advanced ovarian cancer from the TRUST trial.
Panelists discuss how tisotumab vedotin represents a practice-changing but modest improvement in cervical cancer treatment, with only 1.5-month progression-free survival benefit and notable ocular toxicities, while emphasizing the need for better patient access to required ophthalmologic monitoring.
Panelists discuss how cervical cancer treatment guidelines have rapidly evolved to incorporate pembrolizumab across multiple settings, from locally advanced disease with positive nodes to metastatic disease, while emphasizing the importance of comprehensive biomarker testing including PD-L1 and HER2 status for optimal treatment selection.
Panelists discuss how the recent approval of avutometinib plus defactinib for KRAS-mutated low-grade serous ovarian cancer addresses a significant unmet need in this lethal disease, with the dual FAK/MEK inhibition approach showing impressive response rates despite requiring careful toxicity management.
